These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16341811)

  • 1. Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.
    Baser ME; Rai H; Wallace AJ; Evans DG
    Fam Cancer; 2005; 4(4):321-2. PubMed ID: 16341811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofibromatosis 2 and malignant mesothelioma.
    Baser ME; De Rienzo A; Altomare D; Balsara BR; Hedrick NM; Gutmann DH; Pitts LH; Jackler RK; Testa JR
    Neurology; 2002 Jul; 59(2):290-1. PubMed ID: 12136076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
    Menges CW; Kadariya Y; Altomare D; Talarchek J; Neumann-Domer E; Wu Y; Xiao GH; Shapiro IM; Kolev VN; Pachter JA; Klein-Szanto AJ; Testa JR
    Cancer Res; 2014 Feb; 74(4):1261-1271. PubMed ID: 24371224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mouse model recapitulating molecular features of human mesothelioma.
    Altomare DA; Vaslet CA; Skele KL; De Rienzo A; Devarajan K; Jhanwar SC; McClatchey AI; Kane AB; Testa JR
    Cancer Res; 2005 Sep; 65(18):8090-5. PubMed ID: 16166281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma.
    Kleymenova EV; Bianchi AA; Kley N; Pylev LN; Walker CL
    Mol Carcinog; 1997 Jan; 18(1):54-60. PubMed ID: 9022813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
    Bianchi AB; Mitsunaga SI; Cheng JQ; Klein WM; Jhanwar SC; Seizinger B; Kley N; Klein-Szanto AJ; Testa JR
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10854-8. PubMed ID: 7479897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours.
    Fleury-Feith J; Lecomte C; Renier A; Matrat M; Kheuang L; Abramowski V; Levy F; Janin A; Giovannini M; Jaurand MC
    Oncogene; 2003 Jun; 22(24):3799-805. PubMed ID: 12802287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple meningiomas: differential involvement of the NF2 gene in children and adults.
    Evans DG; Watson C; King A; Wallace AJ; Baser ME
    J Med Genet; 2005 Jan; 42(1):45-8. PubMed ID: 15635074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer.
    Sekido Y; Pass HI; Bader S; Mew DJ; Christman MF; Gazdar AF; Minna JD
    Cancer Res; 1995 Mar; 55(6):1227-31. PubMed ID: 7882313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
    Kley N; Whaley J; Seizinger BR
    Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
    Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL
    Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.
    Irving RM; Moffat DA; Hardy DG; Barton DE; Xuereb JH; Maher ER
    Hum Mol Genet; 1994 Feb; 3(2):347-50. PubMed ID: 8004107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis.
    Jacoby LB; MacCollin M; Parry DM; Kluwe L; Lynch J; Jones D; Gusella JF
    Neurogenetics; 1999 Apr; 2(2):101-8. PubMed ID: 10369886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.
    Dinh CT; Nisenbaum E; Chyou D; Misztal C; Yan D; Mittal R; Young J; Tekin M; Telischi F; Fernandez-Valle C; Liu XZ
    Otol Neurotol; 2020 Jun; 41(5):e529-e537. PubMed ID: 32150022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region.
    Pylkkänen L; Sainio M; Ollikainen T; Mattson K; Nordling S; Carpén O; Linnainmaa K; Husgafvel-Pursiainen K
    Oncol Rep; 2002; 9(5):955-9. PubMed ID: 12168054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
    Kley N; Seizinger BR
    Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene.
    Baser ME;
    Hum Mutat; 2006 Apr; 27(4):297-306. PubMed ID: 16521120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Silico Analysis of NF2 Gene Missense Mutations in Neurofibromatosis Type 2: From Genotype to Phenotype.
    Heineman TE; Evans DG; Campagne F; Selesnick SH
    Otol Neurotol; 2015 Jun; 36(5):908-14. PubMed ID: 25931164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vestibular schwannoma growth.
    Tang BH
    J Neurosurg; 2004 Apr; 100(4):734-5; author reply 735. PubMed ID: 15070133
    [No Abstract]   [Full Text] [Related]  

  • 20. Familial mesothelioma in first degree relatives.
    Kalogeraki AM; Tamiolakis DJ; Lagoudaki ED; Papadakis MN; Papadakis GZ; Agelaki SI; Stathopoulos EN; Tzardi MN
    Diagn Cytopathol; 2013 Jul; 41(7):654-7. PubMed ID: 22351650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.